An experimental agent, plinabulin (NPI-2358, BeyondSpring Pharmaceuticals), may increase the efficacy and safety of docetaxel in patients with lung cancer, according a Phase II study presented at the American Society of Clinical Oncology–Society for Immunotherapy of Cancer’s 2017 Clinical Immuno-Oncology Symposium (abstract 139).
Lead investigator Ramon W. Mohanlal, MD, PhD, from BeyondSpring Pharmaceuticals, New York City, explained that plinabulin is a small molecule with